00:25 , Jun 8, 2019 |  BC Extra  |  Politics & Policy

NIDA Director Volkow calls on biotechs to step up to the plate in opioid crisis

Director of NIH’s National Institute On Drug Abuse Nora Volkow called on investors and biotech companies to roll up their sleeves and help end the opioid crisis by contributing their intellectual and financial resources to...
18:42 , Jun 3, 2019 |  BioCentury  |  Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
13:29 , Apr 5, 2019 |  BioCentury  |  Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
20:06 , Dec 14, 2018 |  BC Week In Review  |  Company News

Novartis expands patient recruitment capabilities in deal with TrialSpark

Through a new partnership with TrialSpark (New York), Novartis AG (NYSE:NVS; SIX:NOVN) will build capacity to enhance clinical trial recruitment by creating local trial sites in areas where distance from hospitals prevents participation. Through cloud-based...
23:44 , Oct 18, 2018 |  BC Innovations  |  Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved....
16:25 , May 4, 2018 |  BC Week In Review  |  Company News

UCB, Science 37 to conduct virtual clinical trials

UCB S.A. (Euronext:UCB) and Science 37 Inc. (Los Angeles, Calif.) partnered to conduct virtual clinical trials using Science 37's cloud-based, mobile telemedicine platform. Initial studies will focus on neurology and immunology indications. Science 37 said...
13:56 , May 3, 2018 |  BC Extra  |  Company News

UCB, Science 37 to conduct virtual clinical trials

UCB S.A. (Euronext:UCB) and Science 37 Inc. (Los Angeles, Calif.) partnered to conduct virtual clinical trials using Science 37's cloud-based, mobile telemedicine platform. Initial studies will focus on neurology and immunology indications. Science 37 said...
15:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence. The trial enrolled about...
18:59 , Mar 29, 2018 |  BC Extra  |  Clinical News

MediciNova sinks after meth dependence failure

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) lost $1.74 (15%) to $10.22 on NASDAQ Thursday after reporting that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat...
17:01 , Mar 16, 2018 |  BC Week In Review  |  Company News

IBM cognitive computing speeds Mayo trial enrollment

Mayo Clinic (Rochester, Minn.) and IBM Corp. (NYSE:IBM) said IBM’s Watson for Clinical Trials Matching cognitive computing system increased mean enrollment in Mayo’s systemic therapy clinical trials for breast cancer by 80% in its first...